Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer

Pharmacogenomics

Volumn 6, Issue 6, 2005, Pages 603-614

  Allen, Wendy L ^a   Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Chemotherapy; Colorectal cancer; Implementation; Molecular marker; Profiling; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOOXYGENASE 2; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; INTERLEUKIN 8; IRINOTECAN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MOLECULAR MARKER; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; STAT5 PROTEIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER STAGING; CHROMOSOME 18Q; CLINICAL TRIAL; COLON CANCER; DISEASE SEVERITY; DNA DETERMINATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; GENE MUTATION; HETEROZYGOSITY LOSS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MONOTHERAPY; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN ANALYSIS; PROTEIN MICROARRAY; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINGLE STRAND CONFORMATION POLYMORPHISM;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLONIC NEOPLASMS; FLUOROURACIL; FORECASTING; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; TUMOR MARKERS, BIOLOGICAL;

EID: 25144466613     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.6.603     Document Type: Review

References (119)

1. Johnston PG, Kaye S: Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12(8), 639-646 (2001).
2. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355(9209), 1041-1047 (2000).
3. Giacchetti S, Perpoint B, Zidani R et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 18(1), 136-147 (2000).
4. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinorecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337-345 (2004).
5. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
6. Salonga D, Danenberg KD, Johnson M et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6(4), 1322-1327 (2000).
7. Kern SE, Fearon ER, Tersmette KW et al.: Clinical and pathological associations with allelic loss in colorectal carcinoma (corrected). JAMA 261(21), 3099-3103 (1989).
8. Liu ZG, Baskaran R, Lea-Chou ET et al.: Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384(6606), 273-276 (1996).
9. Buglioni S, D'Agnano I, Vasselli S et al.: p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected Stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. Am. J. Clin. Pathol. 116(3), 360-368 (2001).
10. Gervaz P, Bouzourene H, Cerottini JP et al.: Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location. Dis. Colon Rectum 44(3), 364-372; discussion 372-373 (2001).
11. Bouzourene H, Gervaz P, Cerottini JP et al.: p53 and Ki-ras as prognostic factors for Dukes' Stage B colorectal cancer. Eur. J. Cancer. 36(8), 1008-1015 (2000).
12. Allegra CJ, Paik S, Colangelo LH et al.: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J. Clin. Oncol. 21(2), 241-250 (2003).
13. Giatromanolaki A, Stathopoulos GP, Tsiobanou E et al.: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 86(8), 1421-1430 (1999).
14. Soong R, Grieu F, Robbins P et al.: p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin. Cancer Res. 3(8), 1405-1411 (1997).
15. Bhatavdekar JM, Patel DD, Chikhlikar PR et al.: Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis. Colon Rectum 44(4), 523-533 (2001).
16. Tang R, Wang JY, Fan CW et al.: p53 is an independent pre-treatment markers for long-term survival in Stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett. 210(1), 101-109 (2004).
17. Ahnen DJ, Feigl P, Quan G et al.: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 58(6), 1149-1158 (1998).
18. Lanza G, Matteuzzi M, Gala R et al.: Chromosome 18q allelic loss and prognosis in Stage II and III colon cancer. Int. J. Cancer 79(4), 390-395 (1998).
19. Shibata D, Reale MA, Lavin P et al.: The DCC protein and prognosis in colorectal cancer. N. Engl. J. Med. 335(23), 1727-1732 (1996).
20. Watanabe T, Wu TT, Catalano PJ et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344 (16), 1196-1206 (2001).
21. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
22. Papadimitrakopoulou VA, Oh Y, El-Naggar A, Izzo J, Clayman G, Mao L: Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin. Cancer Res. 4(3), 539-544 (1998).
23. Remvikos Y, Muleris M, Salmon RJ, Dutrillaux B: Colorectal carcinogenesis: from chromosomal evolution pathways to molecular pathogenesis. Cancer Genet. Cytogenet. 93(1), 63-73 (1997).
24. Chai SM, Zeps N, Shearwood AM et al.: Screening for defective DNA mismatch repair in Stage II and III colorectal cancer patients. Clin. Gastroenterol. Hepatol. 2(11), 1017-1025 (2004).
25. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA: Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 61(13), 5193-5201 (2001).
26. Gryfe R, Kim H, Hsieh ET et al.: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342(2), 69-77 (2000).
27. Lim SB, Jeong SY, Lee MR et al.: Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int. J. Colorectal Dis. 19(6), 533-537 (2004).
28. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217), 1745-1750 (2000).
29. Ribic CM, Sargent DJ, Moore MJ et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003).
30. Allegra CJ, Kim G, Kirsch IR: Microsatellite instability in colon cancer. N. Engl. J. Med. 349(18), 1774-1776; author reply 1774-1776 (2003).
31. Roberts AB, Flanders KC, Heine UI et al.: Transforming growth factor-β: multifunctional regulator of differentiation and development. Philos. Trans. R. Soc. Lond. B Biol. Sci. 327(1239), 145-154 (1990).
32. Massague J, Cheifetz S, Boyd FT, Andres JL: TGF-β receptors and TGF-β binding proteoglycans: recent progress in identifying their functional properties. Ann. NY Acad. Sci. 593, 59-72 (1990).
33. Shull MM, Ormsby I, Kier AB et al.: Targeted disruption of the mouse transforming growth factor-β 1 gene results in multifocal inflammatory disease. Nature 359(6397), 693-699 (1992).
34. Kulkarni AB, Huh CG, Becker D et al.: Transforming growth factor-β 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl Acad. Sci. USA 90(2), 770-774 (1993).
35. Houghton JA, Tillman DM, Harwood FG: Ratio of 2′-deoxyadenosine-5′-triphosphate /thymidine-5′-triphosphate influences the commitment of human colon carcinoma cells to thymineless death. Clin. Cancer Res. 1(7), 723-730 (1995).
36. Lehman NL: Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin. Investig. Drugs 11(12), 1775-1787 (2002).
37. Johnston PG, Drake JC, Trepel J, Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res. 52(16), 4306-4312 (1992).
38. Edler D, Glimelius B, Hallstrom M et al.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol. 20(7), 1721-1728 (2002).
39. Nanni O, Volpi A, Frassineti GL et al.: Role of biological markers in the clinical outcome of colon cancer. Br. J. Cancer 87(8), 868-875 (2002).
40. Berglund A, Edler D, Molin D, Nordlinder H, Graf W, Glimelius B: Thymidylate synthase and p53 expression in primary tumor do not predict chemotherapy outcome in metastatic colorectal carcinoma. Anticancer Res. 22(6B), 3653-3659 (2002).
41. Johnston PG, Benson A, Catalano P et al.: The clinical significance of thymidylate synthase (TS) expression in primary colorectal cancer: An Intergroup combined analysis. Proceedings from the 41st annual meeting of the American Society of Clinical Oncology, Orlando, FL, USA (2005).
42. Marsh S, McKay JA, Cassidy J, McLeod HL: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int. J. Oncol. 19(2), 383-386 (2001).
43. Marsh S, McLeod HL: Thymidylate synthase pharmacogenetics in colorectal cancer. Clin. Colorectal Cancer 1(3), 175-178; discussion 179-181 (2001).
44. Kawakami K, Omura K, Kanehira E, Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19(4B), 3249-3252 (1999).
45. Metzger R, Danenberg K, Leichman CG et al.: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. 4(10), 2371-2376 (1998).
46. Takebayashi Y, Miyadera K, Akiyama S et al.: Expression of thymidine phosphorylase in human gastric carcinoma. Jpn. J. Cancer. Res. 87(3), 288-295 (1996).
47. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16(4), 215-237 (1989).
48. +-enriched peripheral blood progenitor cells. Cancer Gene Ther. 8(12), 966-973 (2001).
49. Johnston SJ, Ridge SA, Cassidy J, McLeod HL: Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin. Cancer Res. 5(9), 2566-2570 (1999).
50. Schneider HB, Becker H: Dehydropyrimidine dehydrogenase deficiency in a cancer patient undergoing 5-fluorouracil chemotherapy. Anticancer Res. 24(2C), 1091-1092 (2004).
51. Tsuji T, Sawai T, Takeshita H et al.: Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother. Pharmacol. 54(6), 531-536 (2004).
52. Tsuji T, Sawai T, Takeshita H et al.: Tumor dihydropyrimidine dehydrogenase in Stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. Cancer Lett. 204(1), 97-104 (2004).
53. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V: Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res. 20(2), 267-272 (1992).
54. Adjei AA: A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br. J. Clin. Pharmacol. 48(3), 265-277 (1999).
55. Reardon JT, Vaisman A, Chaney SG, Sancar A: Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res. 59(16), 3968-3971 (1999).
56. Wilson MD, Ruttan CC, Koop BF, Glickman BW. ERCC1: a comparative genomic perspective. Environ. Mol. Mutagen. 38(2-3), 209-215 (2001).
57. Shirota Y, Stoehlmacher J, Brabender J. et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19(23), 4298-4304 (2001).
58. Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S: Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 365(6449), 852-855 (1993).
59. Terrier P, Townsend AJ, Coindre JM, Triche TJ, Cowan KH et al.: An immunohistochemical study of π class glutathione S-transferase expression in normal human tissue. Am. J. Pathol. 137(4), 845-853 (1990).
60. Zhang K, Mack P, Wong KP: Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int. J. Oncol. 12(4), 871-882 (1998).
61. Takimoto CH, Kieffer LV, Arbuck SG: DNA topoisomerase I inhibitors. Cancer Chemother. Biol. Response Modif. 17, 80-113 (1997).
62. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35(41), 13303-13309 (1996).
63. Misset JL, di Palma M, Delgado M et al.: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J. Clin. Oncol. 14(4), 1136-1145 (1996).
64. Rivory LP, Bowles MR, Robert J, Pond SM: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol. 52(7), 1103-1111 (1996).
65. Hsiang YH, Liu LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48(7), 1722-1726 (1988).
66. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E: CPT-11 in human colon-cancer cell lines and xenografts: characterisation of cellular sensitivity determinants. Int. J. Cancer 70(3), 335-340 (1997).
67. Humerickhouse R, Lohrbach K, Li L, Boston WF, Dolan ME: Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res. 60(5), 1189-1192 (2000).
68. Iyer L, King CD, Whitington PF et al.: Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 101(4), 847-854 (1998).
69. Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA. 95(14), 8170-8174 (1998).
70. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2(1), 43-47 (2002).
71. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60(24), 6921-6926 (2000).
72. Zwick E, Hackel PO, Prenzel N, Ullrich A: The EGF receptor as central transducer of heterologous signalling systems. Trends Pharmacol. Sci. 20(10), 408-412 (1999).
73. Ciardiello F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 60(Suppl. 1), 25-32; discussion 41-42 (2000).
74. Salomon DS, Normanno N, Ciardiello F, Brandt R, Shoyab M, Todaro GJ: The role of amphiregulin in breast cancer. Breast Cancer Res. Treat. 33(2), 103-114 (1995).
75. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and MDR gene expression in colorectal cancer. Cancer 71(8), 2454-2460 (1993).
76. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 411(6835), 355-365 (2001).
77. Yarden Y: The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur. J. Cancer 37(Suppl. 4), S3-S8 (2001).
78. McKay JA, Murray LJ, Curran S et al.: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur. J. Cancer 38(17), 2258-2264 (2002).
79. Chi DD, Hing AV, Helms C, Steinbrueck T, Mishra SK, Donis-Keller H: Two chromosome 7 dinucleotide repeat polymorphisms at gene loci epidermal growth factor receptor (EGFR) and pro α 2 (I) collagen (COL1A2). Hum. Mol. Genet. 1(2), 135 (1992).
80. Gebhardt F, Zanker KS, Brandt B: Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 274(19), 13176-13180 (1999).
81. Azzariti A, Xu JM, Porcelli L, Paradiso A: The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with gefitinib (Iressa, ZD1839). Biochem. Pharmacol. 68(1), 135-144 (2004).
82. Mackenzie MJ, Hirte HW, Glenwood G et al.: A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest. New Drugs 23(2), 165-170 (2005).
83. Daneshmand M, Parolin DA, Hirte HW et al.: A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin. Cancer Res. 9(7), 2457-2464 (2003).
84. Veronese ML, Sun W, Giantonio B et al.: A Phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. Br. J. Cancer 92(10), 1846-1849 (2005).
85. Paez JG, Janne PA, Lee JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
86. Lynch TJ, Bell DW, Sordella R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
87. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687), 1163-1167 (2004).
88. Cappuzzo F, Magrini E, Ceresoli GL et al.: Akt phosphorylation and gefitinib efficacy in patients with advanced nonsmall cell lung cancer. J. Natl Cancer Inst. 96(15), 1133-1141 (2004).
89. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6(12), 4885-4892 (2000).
90. Cappuzzo F, Hirsch FR, Rossi E et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall cell lung cancer. J. Natl Cancer Inst. 97(9), 643-655 (2005).
91. Perez-Soler R: The role of erlotinib (Tarceva, OSI 774) in the treatment of nonsmall cell lung cancer. Clin. Cancer Res. 10(12 Pt 2), 4238s-4240s (2004).
92. Delord P, Beale P, Van Cutsemet E et al.: A Phase 1b dose-escalation trial of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer (MCRC) patients. Proceedings of the 2004 ASCO Annual Meeting (Post-Meeting Edition). J. Clin. Oncol. 22(14S), A3585 (2004).
93. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7(10), 2958-2970 (2001).
94. Petit AM, Rak J, Hung MC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151(6), 1523-1530 (1997).
95. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22(7), 1201-1208 (2004).
96. van Laethem R, Raoul JL, Mitry E et al.: Cetuximab (C225) in combination with bi-weekly irinotecan, infusional 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer expressing the epidermal growth factor receptor. Preliminary safety and efficacy results. Proc. Am. Soc. Clin. Oncol. 22, 264 (A1058) (2003).
97. Vallbohmer D, Zhang W, Gordon M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 23(15), 3536-3544 (2005).
98. Meropol N, Berlin J, Hecht J et al.: Multicentre study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Am. Soc. Clin. Oncol. 22, A1026 (2003).
99. Kanno S, Oda N, Abe M et al.: Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19(17), 2138-2146 (2000).
100. Kim KJ et al. : Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumours growth in vivo. Nature 362(6423), 841-844 (1993).
101. Cascinu S, Staccioli MP, Gasparini G et al.: Expression of vascular endothelial growth factor can predict event-free survival in Stage II colon cancer. Clin. Cancer Res. 6(7), 2803-2807 (2000).
102. Ferrara N, Keyt B: Vascular endothelial growth factor: basic biology and clinical implications. EXS 79, 209-232 (1997).
103. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z et al.: Vascular endothelial growth factor (VEGF) and its receptors. Faseb J. 13(1), 9-22 (1999).
104. Ishigami SI, Arii S, Furutani M et al.: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer 78(10), 1379-1384 (1998).
105. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21(1), 60-65 (2003).
106. Giantonio B, Catalano P, Meropol N: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. GI cancers symposium, Hollywood, FL, USA, Abstract169a (2005).
107. Tyagi P: Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin. Colorectal Cancer 5(1), 24-26 (2005).
108. Arango D, Wilson AJ, Shi Q et al.: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 91(11), 1931-1946 (2004).
109. Mariadason JM, Arango D, Shi D, et al.: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63(24), 8791-8812 (2003).
110. Golub TR, Slonim DK, Tamayo P et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999).
111. van de Vijver MJ, He YD, van't Veer LJ et al.: A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
112. Beer DG, Kardia SL, Huang CC et al.: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Med. 8(8), 816-824 (2002).
113. Gordon GJ, Jensen RV, Hsiao LL et al.: Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl Cancer Inst. 95(8), 598-605 (2003).
114. Bertucci F, Finetti P, Rougemont J et al.: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res. 64(23), 8558-8565 (2004).
115. Bertucci F, Salas S, Eysteries S et al.: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23(7), 1377-1391 (2004).
116. Alon U, Barkai N, Notterman DA et al.: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc. Natl Acad. Sci. USA 96(12), 6745-6750 (1999).
117. Wang Y, Jatkoe T, Zhang Y et al.: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol. 22(9), 1564-1571 (2004).
118. Johnston PG, Lenz HJ, Leichman C et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55(7), 1407-1412 (1995).
119. Anderson L, Seilhamer J: A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3-4), 533-537 (1997).